A blockage of glutamine metabolism by DON (6-diazo-5-oxy-L-norleucine), or its modified prodrug JHU-083, causes a shift of CD8+ T cells towards a long-lived memory state and increases their tumor infiltration potential and survival in the TME (46–48). Here, CD8A is linked to neoplasm.